The EPS miss reinforces the bearish sentiment for a pre-revenue biotech with no near-term catalysts until 2027 interim data. The $172.4M cash runway into H2 2028 provides a floor, but without a partnership or data catalyst, the stock is likely to drift lower. Monitor for any partnership or financing announcements given the $76M market cap.
Price Chart
Executive Summary
Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was $0 (pre-revenue biotech). Net loss narrowed to $20.0M from $56.2M a year ago due to lower R&D spend after terminating bexotegrast. The company highlighted early clinical progress for PLN-101095 in ICI-refractory tumors, including a complete response and two partial responses, but the EPS miss and absence of near-term catalysts cap the upside for a $76M market cap stock.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.38 missed consensus of -$0.36 (-6.2% miss)
- Revenue was $0 (pre-revenue clinical-stage biotech)
- Net loss narrowed to $20.0M from $56.2M YoY, driven by lower R&D spend after bexotegrast termination
- Cash, cash equivalents and short-term investments of $172.4M expected to fund operations into H2 2028
- First patient dosed in FORTIFY Phase 1b trial of PLN-101095; interim data expected in 2027
- Updated Phase 1 data at AACR showed 1 complete response, 2 partial responses in ICI-refractory tumors
Financial Impact
EPS miss of $0.02 per share vs consensus; net loss of $20.0M vs $56.2M YoY
Risk Factors
- Clinical trial failure or delay for PLN-101095
- Cash burn rate may accelerate if trials expand
- No revenue and reliance on equity or debt financing
- Competition from other checkpoint resistance therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292302 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 6w ago | Press Release | $1.15 $1.15 | ▼ −0.43% | ▲ +0.55% | $1.03 (−10.00%) |
May 11, 2026 20w ago | 8-K | $1.18 $1.16 | ▼ −1.69% | ▲ +0.03% | $1.03 (−12.29%) |
May 11, 2026 20w ago | Press Release | $1.18 $1.16 | ▲ +1.69% | ▼ −0.03% | $1.03 (+12.29%) |
Apr 17, 2026 23w ago | 8-K | $1.29 $1.18 | ▼ −8.53% | ▼ −12.73% | $1.03 (−19.77%) |
Apr 7, 2026 25w ago | EFFECT | $1.31 $1.19 | ▼ −9.16% | ▼ −18.94% | $1.03 (−20.99%) |
Mar 11, 2026 29w ago | 8-K | $1.41 $1.28 | ▼ −9.22% | ▼ −11.19% | $1.03 (−26.60%) |
Mar 3, 2026 30w ago | 8-K | $1.29 $1.32 | ▲ +2.33% | ▲ +6.74% | $1.03 (−19.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access